--- title: "Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus" type: "News" locale: "en" url: "https://longbridge.com/en/news/284575753.md" description: "Hansoh Pharmaceutical Group has transferred its exclusive Greater China license for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals. This decision follows a strategic review of Hansoh's portfolio. The medical chitosan knee injection, approved by China's NMPA, will now be developed by Hengrui, which has a stronger orthopedic presence. The deal allows Hansoh to recover its development costs for RMB131 million and aligns with its long-term strategic focus. The latest analyst rating for Hansoh stock is a Buy with a price target of HK$47.00." datetime: "2026-04-29T12:45:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284575753.md) - [en](https://longbridge.com/en/news/284575753.md) - [zh-HK](https://longbridge.com/zh-HK/news/284575753.md) --- # Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update. Hansoh Pharmaceutical Group has transferred its exclusive Greater China licence for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals, following a strategic review of its portfolio and resource allocation priorities. The medical chitosan knee injection, approved by China’s NMPA as a medical device in August 2025 but not yet commercialised, will now be developed and marketed by Hengrui, which has a stronger presence in orthopedics. Under a novation and transfer structure, Hansoh’s three original licensee subsidiaries will exit the licence agreement and assign all related rights and obligations to Hengrui for RMB131 million, allowing Hansoh to recover its development costs on a cost basis. The board said the deal, classified as revenue in the ordinary course of business and not a notifiable or connected transaction under Hong Kong listing rules, aligns with Hansoh’s long-term strategic focus while positioning the product with a partner better equipped for its commercial rollout. The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page. **More about Hansoh Pharmaceutical Group Company Limited** Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company engaged in the research, development, manufacture and sale of medicines across multiple therapeutic areas. Through its subsidiaries, the group has historically pursued partnerships and licensing deals to expand its portfolio in key markets including Mainland China, Hong Kong, Macau and Taiwan. **Average Trading Volume:** 9,595,210 **Technical Sentiment Signal:** Strong Buy **Current Market Cap:** HK$234.1B Learn more about 3692 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [600276.CN](https://longbridge.com/en/quote/600276.CN.md) ## Related News & Research - [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md) - [Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC](https://longbridge.com/en/news/285857826.md) - [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md) - [](https://longbridge.com/en/news/286948461.md) - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md)